Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
- 19 April 2023
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (7) , 873
Abstract
We would like to thank for Camps et al. [1] for the very constructive comments.In our Editorial “What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?” published i...Keywords
This publication has 5 references indexed in Scilit:
- Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravisExpert Opinion on Pharmacotherapy, 2023
- What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?Expert Opinion on Pharmacotherapy, 2022
- A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis ExacerbationsEuropean Neurology, 2019
- Comparison of IVIg and PLEX in patients with myasthenia gravisNeurology, 2011
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007